Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ascendis Pharma Q2 EPS $(2.06) Misses $(1.56) Estimate, Sales $38.76M Miss $92.74M Estimate

Author: Benzinga Newsdesk | September 03, 2024 05:07pm
Ascendis Pharma (NASDAQ:ASND) reported quarterly losses of $(2.06) per share which missed the analyst consensus estimate of $(1.56) by 32.05 percent. This is a 12.34 percent increase over losses of $(2.35) per share from the same period last year. The company reported quarterly sales of $38.76 million which missed the analyst consensus estimate of $92.74 million by 58.21 percent. This is a 24.97 percent decrease over sales of $51.66 million the same period last year.

Posted In: ASND


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist